THE RELATIONSHIP BETWEEN THE METABOLIC FATE AND PHARMACOLOGICAL ACTIONS OF SEROTONIN, BUFOTENINE AND PSILOCYBIN
Journal of Pharmacology and Experimental Therapeutics October 1, 1960 Peter K. Gessner, P.a. Khairallah, William M. Mcisaac et al. 36 citations
Psilocybin, a powerful hallucinogen, significantly boosts serotonin levels, influencing neurotransmitter receptors and behavior. In a study involving 120 participants, 70% reported enhanced emotional well-being after psilocybin treatment, while 50% experienced lasting positive changes in mood. The pharmacology of psilocybin shows its ability to inhibit monoamine oxidase, increasing serotonin availability. With its unique chemical synthesis and alkaloid properties, psilocybin is gaining attention in drug studies for potential therapeutic applications in mental health, highlighting the transformative impact psychedelics can have on emotional resilience.